Literature DB >> 21289312

Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.

Michael K Racke1, Amy E Lovett-Racke.   

Abstract

Glatiramer acetate (GA) has been used as an immunomodulatory agent for the treatment of relapsing-remitting multiple sclerosis (MS) in the United States since 1996. It is currently one of two first-line agents for use in the treatment of relapsing-remitting MS. GA was the first agent to be used in the treatment of MS that was developed using the animal model of MS called experimental autoimmune encephalomyelitis. In this commentary, we examine the development of GA as a treatment for MS and discuss its mechanism of action as suggested by recent studies using modern immunologic methods.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21289312     DOI： 10.4049/jimmunol.1090138

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA.

Authors:  Neeraj K Surana; Dennis L Kasper
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

Review 2.  Extremophilic proteases as novel and efficient tools in short peptide synthesis.

Authors:  Aneta M Białkowska; Krzysztof Morawski; Tomasz Florczak
Journal:  J Ind Microbiol Biotechnol       Date:  2017-06-23       Impact factor: 3.346

3.  Autoreactivity against myelin basic protein in patients with chronic paraplegia.

Authors:  D Zajarías-Fainsod; J Carrillo-Ruiz; H Mestre; I Grijalva; I Madrazo; A Ibarra
Journal:  Eur Spine J       Date:  2011-11-08       Impact factor: 3.134

4.  Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.

Authors:  Daniel R Getts; Aaron J Martin; Derrick P McCarthy; Rachael L Terry; Zoe N Hunter; Woon Teck Yap; Meghann Teague Getts; Michael Pleiss; Xunrong Luo; Nicholas J C King; Lonnie D Shea; Stephen D Miller
Journal:  Nat Biotechnol       Date:  2012-11-18       Impact factor: 54.908

5.  Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: differential expression of neurotrophic and gliotrophic factors.

Authors:  Fei Song; Manoj Bandara; Harvinder Deol; Jeffrey A Loeb; Joyce Benjamins; Robert P Lisak
Journal:  J Neuroimmunol       Date:  2013-06-12       Impact factor: 3.478

Review 6.  Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

Authors:  Babak Jalilian; Halldór Bjarki Einarsson; Thomas Vorup-Jensen
Journal:  Int J Mol Sci       Date:  2012-11-09       Impact factor: 5.923

7.  Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.

Authors:  Anne Waschbisch; Monika Atiya; Ralf A Linker; Sergej Potapov; Stefan Schwab; Tobias Derfuss
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

8.  Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis.

Authors:  Dan Yang; Hong-Fei Ji; Xue-Mei Zhang; Hui Yue; Lin Lin; Yu-Yan Ma; Xiang-nan Huang; Jin Fu; Wei-Zhi Wang
Journal:  Mediators Inflamm       Date:  2014-03-23       Impact factor: 4.711

9.  Emotional change-associated T cell mobilization at the early stage of a mouse model of multiple sclerosis.

Authors:  Giuseppa Piras; Lorenza Rattazzi; Adam McDermott; Robert Deacon; Fulvio D'Acquisto
Journal:  Front Immunol       Date:  2013-11-21       Impact factor: 7.561

Review 10.  miRNAs Participate in MS Pathological Processes and Its Therapeutic Response.

Authors:  Ting Wu; Guangjie Chen
Journal:  Mediators Inflamm       Date:  2016-03-17       Impact factor: 4.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.